Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

ucb pharma s.a. - romosozumab - Οστεοπόρωση - Φάρμακα για τη θεραπεία ασθενειών των οστών - evenity ενδείκνυται στην θεραπεία της σοβαρής οστεοπόρωσης σε μετεμμηνοπαυσιακές γυναίκες με υψηλό κίνδυνο κατάγματος.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

esteve pharmaceuticals gmbh - θειοτέπα - hematopoietic stem cell transplantation; neoplasms - Αντινεοπλασματικοί παράγοντες - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

mylan ireland limited (0000011082) unit 35/36, grange parade, baldoyle industrial estate, dublin 13 - sitagliptin hydrochloride monohydrate - film coated tablets - 100mg - sitagliptin hydrochloride monohydrate (8000004805) 113,374mg

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

mylan ireland limited (0000011082) unit 35/36, grange parade, baldoyle industrial estate, dublin 13 - sitagliptin hydrochloride monohydrate - film coated tablets - 50mg - sitagliptin hydrochloride monohydrate (8000004805) 56,687mg

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

mylan ireland limited (0000011082) unit 35/36, grange parade, baldoyle industrial estate, dublin 13 - sitagliptin hydrochloride monohydrate - film coated tablets - 25mg - sitagliptin hydrochloride monohydrate (8000004805) 28,344mg

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

ucb pharma s.a.   - bimekizumab - Ψωρίαση - Ανοσοκατασταλτικά - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

mylan ireland limited, ireland unit 35/36 grange parade, - dublin 13 - sitagliptin hydrochloride monohydrate - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - 25mg/tab - sitagliptin hydrochloride monohydrate 28,344mg - sitagliptin

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

mylan ireland limited, ireland unit 35/36 grange parade, - dublin 13 - sitagliptin hydrochloride monohydrate - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - 100mg/tab - sitagliptin hydrochloride monohydrate 113,374mg - sitagliptin

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

mylan ireland limited, ireland unit 35/36 grange parade, - dublin 13 - sitagliptin hydrochloride monohydrate - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - 50mg/tab - sitagliptin hydrochloride monohydrate 56,687mg - sitagliptin

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - Σακχαρώδης διαβήτης τύπου 2 - Φάρμακα που χρησιμοποιούνται στον διαβήτη - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. θεραπεία τριπλού συνδυασμού) ως επιπρόσθετο στη δίαιτα και την άσκηση σε ασθενείς που δεν ελέγχονται επαρκώς με μέγιστη ανεκτή για αυτούς δόση μετφορμίνης και σουλφονυλουρίας. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.